Related Experiment Video
Updated: May 2, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
[Expression of ERK5 in multidrug-resistant hepatocellular carcinoma cell line]
Feng Yan1, Xiao-Min Wang, Chao Pan
1Postdoctoral Station, Zhongshan Hospital, Xiamen University, Xiamen, China. yanfeng@xmzsh.com
Objective:
To detect the expression of extracellular-signal regulated protein kinase 5 (ERK5) in multidrug-resistant hepatocellular carcinoma cell lines hepG2/ADM and BEL-7402/5-FU and in the parental cell lines (hepG2 and BEL-7402), and study the role of ERK5 in multidrug resistance of hepatocellular carcinoma.
Methods:
MTT assay was used to determine the multidrug resistance (MDR) of hepG2/ADM and BEL-7402/5-FU cells. Real-time PCR and Western blotting were used to detect the expression of ERK5 at mRNA and protein levels in the 4 cell lines.
Results:
The resistance indices to ADM, 5-FU, and CDDP was 12.34, 5.74, and 3.81 in hepG2/ADM cells, and the resistance indices to 5-FU, VCR, OHP, MTX, and ADM was 15.32, 10.08, 5. 85, 6.74 and 3.26 in BEL-7402 cells, respectively. Compared with those in hepG2 and BEL-7402 cells, the ERK5 gene was up-regulated at both mRNA and protein levels in HepG2/ADM cells, but down-regulated at the mRNA level and up-regulated at the protein level in BEL-7402/5-FU cells.
Conclusions:
ERK5 is related to multidrug resistance in HepG2/ADM and BEL-7402/5-FU cells, and may provide new clues for reversing multidrug resistance of hepatocellular carcinoma cells.
Insights
Extracellular-signal regulated protein kinase 5 (ERK5) expression is linked to multidrug resistance in hepatocellular carcinoma cells. This finding offers new strategies for overcoming drug resistance in liver cancer.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Context:
- Hepatocellular carcinoma (HCC) exhibits significant multidrug resistance (MDR).
- Understanding the molecular mechanisms of HCC-MDR is crucial for effective treatment.
- Extracellular-signal regulated protein kinase 5 (ERK5) is a potential mediator in cancer progression.
Purpose:
- To investigate the expression of ERK5 in multidrug-resistant HCC cell lines (hepG2/ADM and BEL-7402/5-FU) compared to their parental counterparts.
- To elucidate the role of ERK5 in the development and maintenance of multidrug resistance in HCC.
Summary:
- The study utilized MTT assays to quantify drug resistance and real-time PCR and Western blotting to assess ERK5 expression at mRNA and protein levels.
- Results indicated differential regulation of ERK5 in resistant cell lines: upregulated in hepG2/ADM and paradoxically regulated (downregulated mRNA, upregulated protein) in BEL-7402/5-FU.
- These findings suggest a complex relationship between ERK5 expression and MDR in HCC.
Impact:
- ERK5 is implicated as a key factor in HCC multidrug resistance.
- The study provides novel insights that may lead to therapeutic strategies for reversing drug resistance in liver cancer.
- Further research into ERK5 modulation could enhance chemotherapeutic efficacy for HCC patients.
More Related Videos
09:13Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2
Published on: October 24, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
